Comparative Pharmacology
Head-to-head clinical analysis: ACCURETIC versus ORETICYL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCURETIC versus ORETICYL FORTE.
ACCURETIC vs ORETICYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCURETIC is a combination of quinapril, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. Quinapril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
Thiazide diuretic; inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
One tablet orally once daily. Initial dose is 20 mg quinapril/12.5 mg hydrochlorothiazide, titrated to maximum 20 mg quinapril/25 mg hydrochlorothiazide.
Hydrochlorothiazide (HCTZ) 50 mg and deserpidine 0.5 mg orally once daily.
None Documented
None Documented
Quinapril: 0.8 hours; Quinaprilat (active): 2 hours in young healthy adults, prolonged to 3-4 hours in elderly or renal impairment.
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Deserpidine: 4-12 hours.
Renal: approximately 90% (60% unchanged, 30% as metabolites). Fecal/biliary: <10%.
Renal excretion: ~70% as hydrochlorothiazide unchanged; ~30% as deserpidine metabolites via bile/feces.
Category C
Category C
ACE Inhibitor/Diuretic Combination
Diuretic Combination